Acyl Glucuronide Drug Metabolites: Toxicological and A

Therapeutic Drug Monitoring
25, 1-16
DOI: 10.1097/00007691-200302000-00001

Citation Report

#	Article	IF	Citations
1	Separation and detection methods for covalent drugâ€“protein adducts. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 797, 63-90.	1.2	47
2	Mycophenolate mofetil in solid-organ transplantation. Expert Opinion on Pharmacotherapy, 2003, 4, 2325-2345.	0.9	67
3	IDENTIFICATION OF GLUTATHIONE-DERIVED METABOLITES FROM AN IP RECEPTOR ANTAGONIST. Drug Metabolism and Disposition, 2004, 32, 1482-1490.	1.7	13
4	Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica, 2004, 34, 755-770.	0.5	18
5	Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics, 2004, 4, 2728-2738.	1.3	46
6	Use of proteinâ€“acrylamide copolymer hydrogels for measuring protein concentration and activity. Analytical Biochemistry, 2004, 329, 180-189.	1.1	27
7	Monitoring immunosuppressive drugs. Handbook of Analytical Separations, 2004, , 273-296.	0.8	1
8	Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)phenyl}ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist. Journal of Medicinal Chemistry, 2004, 47, 2485-2488.	2.9	140
9	cDNA Microarray Analysis Reveals New Candidate Genes Possibly Linked to Side Effects Under Mycophenolate Mofetil Therapy. Transplantation, 2004, 78, 1145-1152.	0.5	18
10	Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. Therapeutic Drug Monitoring, 2004, 26, 600-608.	1.0	65
11	Determinants of Mycophenolic Acid Levels After Renal Transplantation. Therapeutic Drug Monitoring, 2005, 27, 442-450.	1.0	46
12	The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation. Transplantation, 2005, 80, S244-S253.	0.5	91
13	Presystemic and First-Pass Metabolism. , 2005, , 83-101.		0
14	Fully automated liquidâ€“liquid extraction for the determination of a novel insulin sensitizer in human plasma by heated nebulizer and turbo ionspray liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 293-300.	1.2	14
15	ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition, 2005, 33, 803-811.	1.7	43
16	GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition, 2005, 33, 1027-1035.	1.7	160
17	Pharmacokinetic Principles of Immunosuppressive Drugs. American Journal of Transplantation, 2005, 5, 207-217.	2.6	59
19	Chapter 4 Pitfalls in quantitative LC-MS/MS: Metabolite contribution to measured drug concentration. Progress in Pharmaceutical and Biomedical Analysis, 2005, , 65-103.	0.1	1

#	Article	IF	Citations
20	Kinetic studies on the intramolecular acyl migration of Î²-1-O-acyl glucuronides: Application to the glucuronides of (R)- and (S)-ketoprofen, (R)- and (S)-hydroxy-ketoprofen metabolites, and tolmetin by1H-NMR spectroscopy. Xenobiotica, 2005, 35, 715-725.	0.5	20
21	Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews, 2005, 37, 41-213.	1.5	257
22	Glucuronidation in therapeutic drug monitoring. Clinica Chimica Acta, 2005, 358, 2-23.	0.5	47
23	Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins. Steroids, 2005, 70, 285-294.	0.8	14
24	Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 505-526.	1.5	77
25	The Influence of Plant Secondary Metabolites on the Nutritional Ecology of Herbivorous Terrestrial Vertebrates. Annual Review of Ecology, Evolution, and Systematics, 2005, 36, 169-189.	3.8	236
26	IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM. Drug Metabolism and Disposition, 2005, 33, 139-146.	1.7	251
27	Pharmacokinetics, metabolism, excretion and plasma protein binding of14C-levofloxacin after a single oral administration in the Rhesus monkey. Xenobiotica, 2006, 36, 597-613.	0.5	17
28	Acyl Glucuronides:â€‰ Biological Activity, Chemical Reactivity, and Chemical Synthesis. Journal of Medicinal Chemistry, 2006, 49, 6931-6945.	2.9	116
30	Quantification by Liquid Chromatography Tandem Mass Spectrometry of Mycophenolic Acid and Its Phenol and Acyl Glucuronide Metabolites. Clinical Chemistry, 2006, 52, 1962-1964.	1.5	63
31	Synthesis of 1-Î²-O-acyl glucuronides of diclofenac, mefenamic acid and (S)-naproxen by the chemo-selective enzymatic removal of protecting groups from the corresponding methyl acetyl derivatives. Organic and Biomolecular Chemistry, 2006, 4, 3303-3310.	1.5	30
32	Enzymatic Production of Bile Acid Glucuronides Used as Analytical Standards for Liquid Chromatographyâ^'Mass Spectrometry Analyses. Molecular Pharmaceutics, 2006, 3, 293-302.	2.3	23
33	Monitoring drugâ€“protein interaction. Clinica Chimica Acta, 2006, 365, 9-29.	0.5	35
34	Drug Acyl Glucuronides: Reactivity and Analytical Implication. Current Pharmaceutical Analysis, 2006, 2, 259-277.	0.3	13
35	High-Performance Liquid Chromatography Method for the Determination of Mycophenolic Acid and Its Acyl and Phenol Glucuronide Metabolites in Human Plasma. Therapeutic Drug Monitoring, 2006, 28, 116-122.	1.0	46
36	Pharmacokinetics of Mycophenolic Acid and Metabolites in Diabetic Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 95-101.	1.0	29
37	Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring, 2006, 28, 145-154.	1.0	305
38	Separation of a BMS drug candidate and acyl glucuronide from seven glucuronide positional isomers in rat plasma via high-performance liquid chromatography with tandem mass spectrometric detection. Rapid Communications in Mass Spectrometry, 2006, 20, 1776-1786.	0.7	22

#	Article	IF	Citations
39	A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. British Journal of Clinical Pharmacology, 2006, 62, 477-484.	1.1	48
40	Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 509-521.	2.3	73
41	Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detectionâ€"A lack of MS/MS selectivity between a glucuronide conjugate and a phase I metabolite. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 837, 116-124.	1.2	23
42	Mycophenolic Acid 12-h Trough Level Monitoring in Renal Transplantation: Association with Acute Rejection and Toxicity. American Journal of Transplantation, 2006, 6, 121-128.	2.6	132
43	Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. European Journal of Pharmaceutical Sciences, 2006, 29, 205-214.	1.9	55
44	In vivo and in vitro metabolism of dexamethasone in the camel. Veterinary Journal, 2006, 172, 532-543.	0.6	11
45	Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients. Pharmacotherapy, 2006, 26, 1232-1240.	1.2	24
46	Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. Journal of Mass Spectrometry, 2006, 41, 1121-1139.	0.7	142
47	LC-MS Development Strategies for Quantitative Bioanalysis. Current Drug Metabolism, 2006, 7, 491-502.	0.7	179
49	EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS. Drug Metabolism and Disposition, 2006, 34, 145-151.	1.7	57
50	Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Review of Clinical Immunology, 2006, 2, 495-518.	1.3	5
51	Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences. Drug Metabolism and Disposition, 2007, 35, 440-448.	1.7	32
52	Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrology Dialysis Transplantation, 2007, 22, 2440-2448.	0.4	82
53	Therapeutic Monitoring of Mycophenolate Mofetil. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 184-191.	2.2	99
54	Therapeutic Drug Monitoring-Based Clozapine Dosing Recommendations. Therapeutic Drug Monitoring, 2007, 29, 130-131.	1.0	4
55	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenetics and Genomics, 2007, 17, 321-330.	0.7	68
57	Effect of Acidification on Protein Binding of Mycophenolic Acid. Therapeutic Drug Monitoring, 2007, 29, 132-133.	1.0	7
58	Concentrations of Mycophenolic Acid and Glucuronide Metabolites Under Concomitant Therapy With Cyclosporine or Tacrolimus. Therapeutic Drug Monitoring, 2007, 29, 87-95.	1.0	20

#	Article	IF	Citations
59	The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. Transplantation, 2007, 84, 362-373.	0.5	52
60	Internal Standard Selection for Immunosuppressant Drugs Measured by High-Performance Liquid Chromatography Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2007, 29, 131-132.	1.0	20
61	A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif. Chemical Research in Toxicology, 2007, 20, 1954-1965.	1.7	52
62	Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie, 2007, 89, 393-402.	1.3	44
63	NMR Spectroscopic Studies on the in Vitro Acyl Glucuronide Migration Kinetics of Ibuprofen ((Â±)-(R,S)-2-(4-Isobutylphenyl) Propanoic Acid), Its Metabolites, and Analogues. Analytical Chemistry, 2007, 79, 8720-8727.	3.2	45
64	An Improved Chemo-Enzymatic Synthesis of 1-Î²-O-Acyl Glucuronides:â€‰ Highly Chemoselective Enzymatic Removal of Protecting Groups from Corresponding Methyl Acetyl Derivatives. Journal of Organic Chemistry, 2007, 72, 9541-9549.	1.7	20
65	Determination of Degradation Pathways and Kinetics of Acyl Glucuronides by NMR Spectroscopy. Chemical Research in Toxicology, 2007, 20, 876-886.	1.7	63
66	Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients. Clinical Pharmacokinetics, 2007, 46, 13-58.	1.6	481
67	Efficient synthesis of 1Î²-O-acyl glucuronides via selective acylation of allyl or benzyl d-glucuronate. Tetrahedron, 2007, 63, 7596-7605.	1.0	36
68	Formation Pathways and Opioid Activity Data for 3â€Hydroxypyridinium Compounds Derived from Glucuronic Acid and Opioid Peptides by Maillard Processes. Chemical Biology and Drug Design, 2007, 70, 30-39.	1.5	6
69	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1822-1831.	2.6	65
70	Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 863, 36-45.	1.2	12
71	Optimization to eliminate the interference of migration isomers for measuring 1â€Oâ€Î²â€acyl glucuronide without extensive chromatographic separation. Rapid Communications in Mass Spectrometry, 2008, 22, 109-120.	0.7	14
72	Enzyme-assisted synthesis and structure characterization of glucuronic acid conjugates of losartan, candesartan, and zolarsartan. Bioorganic Chemistry, 2008, 36, 148-155.	2.0	27
73	Renal Function as a Predictor of Irinotecan-induced Neutropenia. Clinical Pharmacology and Therapeutics, 2008, 84, 254-262.	2.3	34
74	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochemical Pharmacology, 2008, 76, 763-772.	2.0	50
75	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clinica Chimica Acta, 2008, 389, 87-92.	0.5	32
76	Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330.	6.1	15

#	Article	IF	Citations
77	Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats. Drug Metabolism and Disposition, 2008, 36, 2523-2538.	1.7	75
78	AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. Therapeutic Drug Monitoring, 2008, 30, 439-444.	1.0	40
79	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von MycophenolsÃure in der Transplantationsmedizin: Wo stehen wir?. Laboratoriums Medizin, 2009, 33, 88-98.	0.1	1
80	Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2009, 37, 2008-2017.	1.7	17
81	Identification and characterization of molecular targets of natural products by mass spectrometry. Mass Spectrometry Reviews, 2010, 29, 126-155.	2.8	57
82	Challenges in the indirect quantitation of acylâ€glucuronide metabolites of a cardiovascular drug from complex biological mixtures in the absence of reference standards. Biomedical Chromatography, 2010, 24, 759-767.	0.8	8
83	Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy. Tetrahedron Letters, 2009, 50, 988-991.	0.7	39
84	Pharmaceutical metabolites in the environment: Analytical challenges and ecological risks. Environmental Toxicology and Chemistry, 2009, 28, 2473-2484.	2.2	262
85	Structureâ^'Activity Relationships for Degradation Reaction of 1-Î²-O-Acyl Glucuronides: Kinetic Description and Prediction of Intrinsic Electrophilic Reactivity under Physiological Conditions. Chemical Research in Toxicology, 2009, 22, 158-172.	1.7	40
86	Structureâ^'Activity Relationships for the Degradation Reaction of 1-Î²-O-Acyl Glucuronides. Part 2: Electronic and Steric Descriptors Predicting the Reactivity of 1-Î²-O-Acyl Glucuronides Derived from Benzoic Acids. Chemical Research in Toxicology, 2009, 22, 1559-1569.	1.7	26
87	Structureâ^'Activity Relationships for the Degradation Reaction of 1-Î²-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-Î²-O-Acyl Glucuronides. Chemical Research in Toxicology, 2009, 22, 1998-2008.	1.7	32
88	Regulation of IL2 and NUCB1 in Mononuclear Cells Treated With Acyl Glucuronide of Mycophenolic Acid Reveals Effects Independent of Inosine Monophosphate Dehydrogenase Inhibition. Therapeutic Drug Monitoring, 2009, 31, 31-41.	1.0	3
89	Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid. Therapeutic Drug Monitoring, 2009, 31, 542-548.	1.0	26
90	Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2009, 31, 205-210.	1.0	13
92	Therapeutic Monitoring of Mycophenolate in Transplantation: Is It Justified?. Current Drug Metabolism, 2009, 10, 179-187.	0.7	32
93	Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm. Mini-Reviews in Medicinal Chemistry, 2009, 9, 703-716.	1.1	31
94	Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2010, 60, 55-62.	1.2	19
95	Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Archives of Toxicology, 2010, 84, 37-43.	1.9	23

#	Article	IF	Citations
96	The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients. European Journal of Clinical Pharmacology, 2010, 66, 671-679.	0.8	10
97	The nasty surprise of a complex drugâ€“drug interaction. Drug Discovery Today, 2010, 15, 391-395.	3.2	21
98	Systematic LCâ€“MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thoughtâ€•out chromatography. Biomedical Chromatography, 2010, 24, 2-19.	0.8	179
99	Acyl glucuronides: the good, the bad and the ugly. Biopharmaceutics and Drug Disposition, 2010, 31, 367-395.	1.1	156
100	The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro. Clinical Biochemistry, 2010, 43, 208-213.	0.8	6
101	Metabolites in Safety Testing: â€œMISTâ€•for the Clinical Pharmacologist. Clinical Pharmacology and Therapeutics, 2010, 87, 345-350.	2.3	39
102	Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity. Drug Metabolism and Disposition, 2010, 38, 1567-1575.	1.7	73
103	Functional Characterization of Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) in the Basolateral Efflux of Glucuronide Conjugates in the Mouse Small Intestine. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 659-666.	1.3	25
104	Uronic Acids in Oligosaccharide and Glycoconjugate Synthesis. Topics in Current Chemistry, 2010, 301, 253-289.	4.0	46
105	The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver. Journal of Biological Chemistry, 2010, 285, 1113-1121.	1.6	19
106	Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics, 2010, 11, 369-390.	0.6	47
107	Direct Analysis of Glucuronides with Liquid Chromatography-Mass Spectrometric Techniques and Methods. Current Drug Metabolism, 2010, 11, 561-582.	0.7	27
108	Rapid resolution of persistent mycophenolate mofetil-induced diarrhoea with a single dose of infliximab. Nephrology Dialysis Transplantation, 2010, 25, 3437-3438.	0.4	11
110	Pharmacokinetics, Metabolism, and Disposition of Deferasirox in Î²-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State. Drug Metabolism and Disposition, 2010, 38, 808-816.	1.7	72
111	Genetic polymorphisms influence mycophenolate mofetilâ€“related adverse events in pediatric heart transplant patients. Journal of Heart and Lung Transplantation, 2010, 29, 509-516.	0.3	52
112	Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncology, 2010, 6, 1897-1913.	1.1	15
113	Reactivity Tuning in Oligosaccharide Assembly. Topics in Current Chemistry, 2011, , .	4.0	23
114	Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Research, 2011, 13, R57.	2.2	38

#	Article	IF	Citations
115	The Pharmacokinetics of Enteric-Coated Mycophenolate Sodium and Its Gastrointestinal Side Effects in De Novo Renal Transplant Recipients of Hispanic Ethnicity. Therapeutic Drug Monitoring, 2011, 33, 45-49.	1.0	11
116	Association Between Pharmacodynamic Biomarkers and Clinical Events in the Early Phase After Kidney Transplantation: A Single-Center Pilot Study. Therapeutic Drug Monitoring, 2011, 33, 341-349.	1.0	17
117	Iso-glucuronides. Current Drug Metabolism, 2011, 12, 222-228.	0.7	12
118	Duodenal Villous Atrophy: A Cause of Chronic Diarrhea After Solid-Organ Transplantation. American Journal of Transplantation, 2011, 11, 575-582.	2.6	76
119	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Reviews, 2011, 25, 47-57.	1.2	116
120	Development and validation of an HPLCâ€“MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Analytical and Bioanalytical Chemistry, 2011, 401, 1023-1034.	1.9	48
121	Detection of naproxen and its metabolites in fish bile following intraperitoneal and aqueous exposure. Environmental Science and Pollution Research, 2011, 18, 811-818.	2.7	33
122	Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Science, 2011, 9, 57.	0.7	16
123	Strategies in quantitative LCâ€MS/MS analysis of unstable small molecules in biological matrices. Biomedical Chromatography, 2011, 25, 258-277.	0.8	117
124	Toxicological Evaluation of Acyl Glucuronides of Nonsteroidal Anti-Inflammatory Drugs Using Human Embryonic Kidney 293 Cells Stably Expressing Human UDP-Glucuronosyltransferase and Human Hepatocytes. Drug Metabolism and Disposition, 2011, 39, 54-60.	1.7	41
125	The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 386-393.	2.5	31
126	Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment. Drug Metabolism and Disposition, 2011, 39, 123-131.	1.7	18
127	Diabetes Mellitus Reduces Activity of Human UDP-Glucuronosyltransferase 2B7 in Liver and Kidney Leading to Decreased Formation of Mycophenolic Acid Acyl-Glucuronide Metabolite. Drug Metabolism and Disposition, 2011, 39, 448-455.	1.7	34
128	Severe Neutropenia in a Renal Transplant Patient Suggesting an Interaction Between Mycophenolate and Fenofibrate. Current Drug Safety, 2012, 7, 24-29.	0.3	11
134	Exploring and Exploiting the Reactivity of Glucuronic Acid Donors. Journal of Organic Chemistry, 2012, 77, 108-125.	1.7	31
135	The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clinica Chimica Acta, 2012, 413, 1318-1325.	0.5	27
136	Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta, 2012, 413, 1839-1847.	0.5	57
139	Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases. Toxicology in Vitro, 2012, 26, 1286-1293.	1.1	9

#	Article	IF	Citations
142	Quantification of Glucuronide Metabolites in Biological Matrices by LC-MS/MS. , 0, , .		11
143	Analytical Methods for Quantification of Drug Metabolites in Biological Samples. , 0, , .		16
144	Esterase inhibitors as esterâ€containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2012, 26, 1291-1304.	0.7	11
145	Pharmacokinetics and pharmacodynamics of mycophenolate sodium (ECâ€MPS) coâ€administered with cyclosporine in the earlyâ€phase postâ€kidney transplantation. Clinical Transplantation, 2012, 26, 57-66.	0.8	14
146	Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions. Inflammatory Bowel Diseases, 2013, 19, 445-456.	0.9	50
147	High-sensitivity liquid chromatographyâ€“tandem mass spectrometry method for the simultaneous determination of sodium picosulfate and its three major metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 915-916, 1-7.	1.2	3
148	Reversible Inhibition of Human Carboxylesterases by Acyl Glucuronides. Drug Metabolism and Disposition, 2013, 41, 698-703.	1.7	8
149	Drugâ€induced Liver Injury: The Role of Drug Metabolism and Transport. Journal of Clinical Pharmacology, 2013, 53, 463-474.	1.0	126
152	Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B, 2013, 3, 289-296.	5.7	13
153	Profiling Serum Bile Acid Glucuronides in Humans: Gender Divergences, Genetic Determinants, and Response to Fenofibrate. Clinical Pharmacology and Therapeutics, 2013, 94, 533-543.	2.3	35
155	Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LCâ€“MS/MS and Library Search. Analytical Chemistry, 2013, 85, 3730-3738.	3.2	108
156	Metabolism Studies In Vitro and In Vivo. , 2013, , 1053-1094.		3
157	Sandwich-cultured hepatocytes: utility forin vitroexploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 589-616.	1.5	110
158	The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews, 2013, 33, 985-1080.	5.0	73
159	In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. Archives of Toxicology, 2013, 87, 1569-1579.	1.9	21
160	Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics, 2013, 14, 1099-1118.	0.6	29
161	A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes. Xenobiotica, 2013, 43, 853-861.	0.5	14
162	In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis. Clinical Chemistry, 2013, 59, 1108-1117.	1.5	45

#	Article	IF	Citations
163	Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry. Journal of Mass Spectrometry, 2014, 49, 57-67.	0.7	2
164	Evaluation of In Situ Generated Valproyl 1-O-Î²-Acyl Glucuronide in Valproic Acid Toxicity in Sandwich-Cultured Rat Hepatocytes. Drug Metabolism and Disposition, 2014, 42, 1834-1842.	1.7	10
165	PharmGKB summary. Pharmacogenetics and Genomics, 2014, 24, 73-79.	0.7	61
166	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Analytical and Bioanalytical Chemistry, 2014, 406, 785-792.	1.9	25
168	Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein. Chemical Science, 2014, 5, 3789-3794.	3.7	18
169	Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2014, 74, 63-75.	1.1	47
170	Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions. Experimental Cell Research, 2014, 322, 277-289.	1.2	40
172	Synthesis of Migrastatin Analogues as Inhibitors of Tumour Cell Migration: Exploring Structural Change in and on the Macrocyclic Ring. Chemistry - A European Journal, 2015, 21, 18109-18121.	1.7	17
173	Exposureâ€“effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. British Journal of Clinical Pharmacology, 2015, 80, 1064-1075.	1.1	12
174	Sensitive and validated LCâ€MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. Biomedical Chromatography, 2015, 29, 1309-1316.	0.8	27
175	Bio-generation of stable isotope-labeled internal standards for absolute and relative quantitation of phase II drug metabolites in plasma samples using LCâ€“MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 4053-4063.	1.9	9
176	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. AAPS Journal, 2015, 17, 660-677.	2.2	94
177	Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats. Biopharmaceutics and Drug Disposition, 2015, 36, 34-48.	1.1	2
178	Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatographyâ€“high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 386-399.	1.4	22
179	How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity / Kako polimorfizmi gena citokroma P450 utjeÄu na metabolizam i toksiÄnost ibuprofena i diklofenaka. Arhiv Za Higijenu Rada I Toksikologiju, 2016, 67, 1-8.	0.4	40
180	High-Throughput HPLC-MS/MS Method for Quantification of Ibuprofen Enantiomers in Human Plasma: Focus on Investigation of Metabolite Interference. Journal of Chromatographic Science, 2016, 54, 1820-1826.	0.7	6
181	Simultaneous quantification of propranolol and sulfamethoxazole and major human metabolite conjugates 4-hydroxy-propranolol sulfate and sulfamethoxazole-Î²-glucuronide in municipal wastewaterâ€”A framework for multiple classes of drugs and conjugates. Journal of Chromatography A, 2016, 1471, 34-44.	1.8	19
182	Diversity of sugar acceptor of glycosyltransferase 1 from Bacillus cereus and its application for glucoside synthesis. Applied Microbiology and Biotechnology, 2016, 100, 4459-4471.	1.7	18

#	Article	IF	Citations
183	In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis. Forensic Toxicology, 2016, 34, 179-185.	1.4	13
184	Hepatic effects of repeated oral administration of diclofenac to hepatic cytochrome P450 reductase null (HRNâ„¢) and wild-type mice. Archives of Toxicology, 2016, 90, 853-862.	1.9	5
185	Regioselective Carbohydrate Oxidations: A Nuclear Magnetic Resonance (NMR) Study on Selectivity, Rate, and Side-Product Formation. ACS Catalysis, 2017, 7, 1438-1445.	5.5	23
186	Detection of metabolites of two synthetic cannabimimetics, MDMB-FUBINACA and ADB-FUBINACA, in authentic human urine specimens by accurate mass LCâ€“MS: a comparison of intersecting metabolic patterns. Forensic Toxicology, 2017, 35, 284-300.	1.4	23
187	Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metabolism Reviews, 2017, 49, 105-138.	1.5	82
188	Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplantation Proceedings, 2017, 49, 26-31.	0.3	11
189	Rapid quantification of free and glucuronidated THCCOOH in urine using coated well plates and LCâ€“MS/MS analysis. Bioanalysis, 2017, 9, 485-496.	0.6	10
190	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica, 2017, 47, 1077-1089.	0.5	5
191	11-nor-9-carboxy-Î” 9 -tetrahydrocannabinol glucuronide exhibits acyl-migration isomers. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 261-265.	1.4	10
192	LCâ€“MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clinical Mass Spectrometry, 2017, 3, 41-48.	1.9	4
193	Prediction of metabolites of epoxidation reaction in MetaTox. SAR and QSAR in Environmental Research, 2017, 28, 833-842.	1.0	12
194	Overcoming challenges associated with the bioanalysis of an ester prodrug and its active acid metabolite. Bioanalysis, 2017, 9, 1589-1601.	0.6	6
195	Procedure for setting control for the turnover of new, potentially hazardous psychoactive substances. Detection of metabolites of a new APINAC psychoactive compound in rat urine by gas and liquid chromatography with mass spectrometry detection. Journal of Analytical Chemistry, 2017, 72, 1193-1202.	0.4	0
196	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 5816-5825.	2.9	35
197	Toxicological role of an acyl glucuronide metabolite in diclofenacâ€induced acute liver injury in mice. Journal of Applied Toxicology, 2017, 37, 545-553.	1.4	25
198	Pharmacokinetics and Genomics of Immunosuppressive Drugs. , 2017, , 429-443.		1
199	Safety Assessment of Acyl Glucuronidesâ€”A Simplified Paradigm. Drug Metabolism and Disposition, 2018, 46, 908-912.	1.7	34
200	Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans. Drug Metabolism and Pharmacokinetics, 2018, 33, 9-16.	1.1	50

#	Article	IF	Citations
201	Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. Chemico-Biological Interactions, 2018, 279, 102-110.	1.7	2
202	Impact ofÂUGT2B7Âand ABCC2Âgenetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Pharmacogenomics, 2018, 19, 1323-1334.	0.6	12
203	Distribution and fate of pharmaceuticals and their metabolite conjugates in a municipal wastewater treatment plant. Water Research, 2018, 144, 774-783.	5.3	67
204	Densitometry and indirect normalâ€phase HPTLCâ€“ESIâ€“MS for separation and quantitation of drugs and their glucuronide metabolites from plasma. Biomedical Chromatography, 2019, 33, e4602.	0.8	7
205	A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Clinical Pharmacokinetics, 2019, 58, 1577-1593.	1.6	16
206	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. Transplantation, 2019, 103, 2012-2030.	0.5	43
207	The importance of evaluating the chemical structures and strategies to avoid pitfalls in quantitative bioanalysis. Bioanalysis, 2019, 11, 85-101.	0.6	3
208	Mycophenolic acid in patients with immuneâ€mediated inflammatory diseases: From humans to dogs. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 127-138.	0.6	13
209	Bioanalytical challenges and strategies for accurately measuring acyl glucuronide metabolites in biological fluids. Biomedical Chromatography, 2020, 34, e4640.	0.8	9
210	Translocation of pharmaceuticals and personal care productsÂafter land application of biosolids. Current Opinion in Environmental Science and Health, 2020, 14, 23-30.	2.1	22
211	Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: What we should know about them?. Artificial Organs, 2020, 44, 561-576.	1.0	10
212	Novel Tricyclic Pyroglutamide Derivatives as Potent RORÎ³t Inverse Agonists Identified using a Virtual Screening Approach. ACS Medicinal Chemistry Letters, 2020, 11, 2510-2518.	1.3	12
213	Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 201-213.	1.5	14
214	Azatricyclic Inverse Agonists of RORÎ³t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis. ACS Medicinal Chemistry Letters, 2021, 12, 827-835.	1.3	3
215	Ataluren metabolism: Ataluren-O-1Î²-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human. Drug Metabolism and Pharmacokinetics, 2021, 38, 100393.	1.1	1
216	Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 â^'106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 713-722.	0.4	4
218	Atalurenâ€"Promising Therapeutic Premature Termination Codon Readthrough Frontrunner. Pharmaceuticals, 2021, 14, 785.	1.7	22
219	Nuclear Receptor-Mediated Regulation of Phase II Conjugating Enzymes. , 0, , 61-110.		3

#	Article	IF	Citations
220	Metabolism Studies in vitro and in vivo. , 2006, , 493-520.		6
222	In situ kinetics of human pharmaceutical conjugates and the impact of transformation, deconjugation, and sorption on persistence in wastewater batch bioreactors. Environmental Pollution, 2020, 265, 114852.	3.7	12
223	Impacts of Pharmaceuticals on Terrestrial Wildlife. Issues in Environmental Science and Technology, 2015, , 216-254.	0.4	4
224	Strategies and Techniques for Bioanalytical Assays as Part of New Drug Discovery. , 2009, , 1-31.		2
225	Challenges and recommendations in developing LCâ€“MS/MS bioanalytical assays of labile glucuronides and parent compounds in the presence of glucuronide metabolites. Bioanalysis, 2020, 12, 615-624.	0.6	7
226	A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. British Journal of Clinical Pharmacology, 2006, .	1.1	0
227	Clinical Pharmacologic Principles and Immunosuppression. , 2011, , 87-109.		0
228	Mycophenolates. , 2014, , 250-266.		0
230	Comparison of Pfannenstiel or Extended Iliac Port Site Kidney Extraction in Laparoscopic Donor Nephrectomy: Do We Have Consensus?. Experimental and Clinical Transplantation, 2018, 16, 138-142.	0.2	4
231	ADME Principles in Small Molecule Drug Discovery and Development: An Industrial Perspective. , 2022, , 51-76.		2
232	Molekulare Mechanismen der Pharmakokinetik. , 2006, , 19-49.		0
233	LCâ€“MS/MS quantification of ataluren and ataluren acyl glucuronide in human plasma/urine: application in clinical studies. Bioanalysis, 2020, 12, 1545-1555.	0.6	0
235	Mycophenolate mofetil alters the antioxidant status in duodenum of rats: Implication for silymarin usage in mycophenolate mofetil-induced gastrointestinal disorders. Veterinary Research Forum, 2013, 4, 77-83.	0.3	2
236	Driving to a Better Understanding of Acyl Glucuronide Transformations Using NMR and Molecular Modeling. Chemical Research in Toxicology, 2022, 35, 459-474.	1.7	2
237	Investigation of Human in vivo Metabolism of SEP-227900 Using the Samples from a Randomized First-in-Human Study by LC-UV/HRMS and NMR. Drug Metabolism Letters, 2022, 15, .	0.5	0
238	The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients. Personalized Medicine, 2022, 19, 383-393.	0.8	1
239	¹⁸O-Enabled High-Throughput Acyl Glucuronide Stability Assay. Chemical Research in Toxicology, 2022, 35, 1400-1409.	1.7	0
241	Acyl Glucuronide and Coenzyme A Thioester Metabolites of Carboxylic Acid-Containing Drug Molecules: Layering Chemistry with Reactive Metabolism and Toxicology. Chemical Research in Toxicology, 2022, 35, 1777-1788.	1.7	5

#	Article	IF	Citations
242	Occurrence of Pharmaceutical and Pesticide Transformation Products in Freshwater: Update on Environmental Levels, Toxicological Information and Future Challenges. Reviews of Environmental Contamination and Toxicology, 2022, 260, .	0.7	2
243	Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities. Bioorganic and Medicinal Chemistry, 2023, 85, 117273.	1.4	1
245	The Prevalence of Several Treatments in Preventing the Back Conversion of Acyl Glucuronide Metabolites in Abbreviated New Drug Applications. AAPS Journal, 2023, 25, .	2.2	0
249	Quantification of Mycophenolic Acid in Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods in Molecular Biology, 2024, , 329-336.	0.4	0